Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Chemed Corp can feel like tackling two companies at once: hospice care economics in VITAS and emergency plumbing metrics in Roto-Rooter. That split shows up in every 10-K footnote, Form 4 footnote, and 8-K headline, making Chemed’s SEC filings unusually dense.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Whether you need the latest Chemed quarterly earnings report 10-Q filing or want Chemed Form 4 insider transactions real-time, our platform surfaces the numbers and narrative in plain language. Instantly pinpoint hospice reimbursement rate disclosures, segment operating margins, and technician labor costs—without wading through hundreds of pages.
All Chemed filings arrive minutes after EDGAR posts. Click into:
- 10-K annual report—AI highlights VITAS patient census trends and Roto-Rooter service revenue (Chemed annual report 10-K simplified).
- 10-Q quarterly update—Compare sequential hospice margins with a one-click Chemed earnings report filing analysis.
- 8-K material events—Get alerts when Medicare rules change (Chemed 8-K material events explained).
- Form 4—Monitor executive stock moves, including CEO transactions (Chemed insider trading Form 4 transactions, Chemed executive stock transactions Form 4).
- Proxy statement (DEF 14A)—Understand how compensation aligns with both segments (Chemed proxy statement executive compensation).
Need context fast? Our summaries answer common questions like “understanding Chemed SEC documents with AI” or “where can I find Chemed’s hospice segment revenue?”. Save hours, stay informed, and make confident decisions with filings explained simply.
Chemed Corp (CHE) reported an insider equity award on Form 4. Joel L. Wherley, CEO of VITAS Healthcare, received a stock option grant covering 17,476 shares at an exercise price of $443.79 on 10/21/2025.
The options vest in three equal annual installments commencing 10/21/2026 and expire on 10/21/2030. Following the transaction, Wherley beneficially owned 32,819 derivative securities directly. No non-derivative share transactions were reported in Table I.
Chemed Corp (CHE) executive vice president Spencer S. Lee reported a stock option grant. On 10/21/2025, he received 12,759 stock options with an exercise price of $443.79 per share, expiring on 10/21/2030. The options vest in three equal annual installments beginning 10/21/2026. Following this grant, he beneficially owned 28,196 derivative securities, held directly.
Chemed Corp (CHE) reported an insider equity award. On 10/21/2025, the company granted its VP and Chief Legal Officer a stock option for 15,017 shares at an exercise price of $443.79 per share, expiring on 10/21/2030. The option vests in three equal annual installments commencing 10/21/2026. After this grant, the reporting person beneficially owned 38,067 derivative securities, held directly.
Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025. Each option has an exercise price of $443.79 and is a right to buy capital stock, expiring on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following this transaction, the reporting person beneficially owned 53,970 derivative securities, held in Direct ownership form.
Chemed Corp (CHE) reported an insider equity award. Director and vice president Thomas C. Hutton filed a Form 4 showing a grant of 6,338 stock options on 10/21/2025, with an exercise price of $443.79 per share. The options relate to Chemed capital stock and expire on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following the reported transaction, Hutton beneficially owned 26,718 derivative securities. Ownership is reported as direct.
Chemed Corp (CHE) reported an insider equity award. CEO and Director Kevin J. McNamara received a grant of stock options covering 58,672 shares on 10/21/2025, with an exercise price of $443.79 per share. The options expire on 10/21/2030 and vest in three equal annual installments starting 10/21/2026. Following this award, he directly holds 266,159 derivative securities. No non-derivative transactions were listed in the excerpt.
Kevin J. McNamara, President, CEO and a director of Chemed Corporation (CHE), reported an open-market sale of 3,000 shares of Chemed common stock on 09/26/2025. The reported weighted-average sale price was $461.28 per share (transactions ranged from $460.03 to $462.44). After the sale the reporting person beneficially owned 96,197 shares. The Form 4 includes an offer to provide transaction-level price/volume details on request.
Form 144 notice for Chemed Corporation (CHE) shows proposed sales of common stock tied to awards granted in 2022. The filing names Kevin McNamara as the seller and lists Merrill Lynch as the broker. It records two stock awards of 1,000 shares each acquired on 05/02/2022 and 08/18/2022 through stock exercise, and indicates an intended sale of 2,000 shares with an aggregate market value of $857,107. The form also records a sale by Kevin McNamara of 2,000 shares on 08/05/2025. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal warnings.
Form 144 filed for CHEMED CORP (CHE) reporting a proposed sale of 1,000 common shares through Raymond James & Associates with an aggregate market value of $460,000.00. The shares were acquired as a stock award on 02/18/2016 and the approximate sale date is 09/26/2025. The filing states there are 14,517,000 shares outstanding for the class. The filer also reports a prior sale of 2,000 common shares on 08/05/2025 generating $857,107.00 in gross proceeds. The notice includes the required representation that the person signing does not possess undisclosed material adverse information.
Insider sale reported by a company director. The Form 4 shows Patrick P. Grace, a Chemed Corp (CHE) director, sold 150 shares on 09/09/2025 at $463.39 per share. After the sale he directly beneficially owns 3,397 shares. No derivative transactions were reported and the filing is by one reporting person.
FAQ
What is the current stock price of Chemed (CHE)?
What is the market cap of Chemed (CHE)?
